Location · Bloomfield, NJ
Clinical trials in Bloomfield, NJ
8 recruiting studies have a site in Bloomfield, and 0 of them accept healthy volunteers.
8 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Bloomfield, NJ + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EyeBiotech Ltd.
- Location
- Bloomfield, NJ + 54 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Bloomfield, NJ + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Bloomfield, NJ + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 4
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
Neurotech Pharmaceuticals
- Location
- Bloomfield, NJ + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Bloomfield, NJ + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Bloomfield, NJ + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Bloomfield, NJ + 77 other US sites
- Eligibility basics
- Ages 60+